Alector (ALEC) Stock
Clinical-stage biotech developing immune therapies for brain diseases. Here's the price, business snapshot, and what's worth knowing about Alector in October 2026.
Alector Inc (NASDAQ: ALEC) is a clinical-stage biopharmaceutical company focused on immuno‑neurology, developing therapies that modulate the immune system to treat neurodegenerative diseases such as Alzheimer’s and ALS. With a market capitalisation of about $324.89M, it sits in the small‑cap, high‑risk segment where valuation is often driven by trial results and regulatory milestones rather than steady revenues. Investors should be aware that Alector’s value is closely tied to the progress of its pipeline, partnering agreements and its ability to raise further capital. Clinical outcomes can be binary and may produce sharp share price moves. Key factors to watch include upcoming data readouts, cash runway, collaboration deals and regulatory interactions. This is general educational information and not personalised investment advice — biotech investing carries significant risk and investors should consider suitability, diversification and time horizon before exposure.
Alector (ALEC) Stock Forecast
Analyst price target, next 12 months
$4.71
+160.5% vs today's $1.81
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Alector have a consensus 12-month target of $4.71, above the current price of $1.81.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Alector's stock with a target price of $4.71, indicating potential growth.
Financial Health
Alector Inc has modest revenue and cash flow, indicating stable but unremarkable financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical data readouts and regulatory milestones can move the share price significantly; outcomes are binary and uncertain, so monitor timelines closely.
Scientific Approach
Alector targets innate immune pathways in neurodegeneration, an emerging scientific area with potential upside but considerable biological and execution risk.
Capital & Partnerships
As a small‑cap developer, Alector may rely on partnerships or financing to fund operations; such moves can de‑risk programmes but may dilute existing shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
